Central Canada includes Manitoba, Nunavut and Saskatchewan!


Here in the Central Region for Crohn's and Colitis Canada, we have a strong community of volunteers, donors and sponsors, as well as an innovative team of researchers and health professionals. These people are the heart and soul of our organization, and there are so many exciting ways to get involved. Every community, large or small, has the potential to help us improve the lives of those affected by Crohn’s disease and ulcerative colitis, and bring us closer to finding cures.

Coordinator, Development and Community Engagement
Tracey Baliski
 
1-306-209-8040

Outside Saskatoon: 1-844-664-4420
Saskatchewan Mailing Address
P.O. Box 28074 RPO Westgate
Saskatoon, SK
S7N 5V8

Outside Manitoba: 1-866-856-8551 (toll free)
Manitoba Mailing Address
PO Box 20009
Winnipeg MB 
R3K 2E5

Woman sitting on her bed looking at her laptop holding a coffee cup

Saskatchewan Peer Connect Event (With Manitoba)

Ready to connect with those who understand the challenges of Crohn’s disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD)?  Join our upcoming Peer Connect ...

 • 
Virtual
 • 
Woman sitting looking at her computer

Canada Wide Peer Connect Event

Ready to connect with those who understand the challenges of Crohn’s disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD)?   Join our upcoming Peer Connect ...

 • 
Virtual
 • 
A young girl watching her senior mother interact with Crohn's and Colitis Connect from a tablet device

Caregiver Peer Connect Event

Ready to connect with those who understand the challenges of being a caregiver to someone with Crohn’s disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD)?   ...

 • 
Virtual
 • 
Remember to bookmark this page.

Saskatchewan Office

PO Box 28074 RPO Westgate
Saskatoon, SK S7M 5V88

saskatchewan@crohnsandcolitis.ca 1-844-664-4420 1-844-664-4420

Search by Postal Code

News

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Send an eCard to Friends or Family Members in Support of Crohn's and Colitis Canada

Send an eCard to Friends or Family Members in Support of Crohn's and Colitis Canada

Today, September 30, Marks the Second National Day for Truth and Reconciliation in Canada

Today, September 30, Marks the Second National Day for Truth and Reconciliation in Canada

 13 14 15 16 17 18 19 20 21 22